Rxsight (RXST) reported $134M in revenue for fiscal 2025, −3.9% year on year. That ranks #2828 by revenue among 2853 SEC filers and #316 in Healthcare. It posted a net loss of −$38.9M for the same year. Revenue has grown 55.7% a year on average since 2020 ($14.7M then). The fiscal 2025 balance sheet shows $312M in total assets, $19.9M in cash and $0 in long-term debt.
Scale corrected: the company's XBRL data reports net income (×10⁶) without the scale factor (for example "4,801" for 4.8 billion). The figures are shown at the corrected scale; each links to the filing it comes from.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $134M | −3.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $103M | +4.1% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$48.2M | −$11.3M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$38.9M | −$11.4M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$15.5M | +$1.4M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $3.8M | −29.6% | FY20252025-12-31 |
| Total assetsAssets | $312M | −2.1% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $276M | −2.0% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $19.9M | +19.4% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $0 | −100.0% | FY20232023-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $30.9M | −$15.9M | Open → |
| Q2 20262026-06-30 | $33.7M | −$12.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Rxsight, Inc.
- Ticker
- RXST
- Exchange
- Nasdaq
- SIC classification
- Ophthalmic Goods (3851)
- Fiscal year end
- 12-31
- CIK
- 0001111485
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 6, 2026Open filing →
- 10-KFeb 25, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Infusystem HoldingsINFU | $143M | $6.6M |
| Beam TherapeuticsBEAM | $140M | −$80.0M |
| NRC HealthNRC | $137M | $11.6M |
| RxsightRXST | $134M | −$38.9M |
| Xtant MedicalXTNT | $134M | $4,973 |
| RidgetechRDGT | $132M | −$1.3M |
| Natural Alternatives InternationalNAII | $130M | −$13.6M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Rxsight — Key figures |url=https://companiesranked.com/en/company/rxsight |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Rxsight — Key figures. CompaniesRanked. https://companiesranked.com/en/company/rxsightBibTeX
@misc{companiesranked-en-company-rxsight-2026,
author = {{CompaniesRanked}},
title = {{Rxsight — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/rxsight}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-071775 · February 25, 2026
{{cite web |title=Rxsight — Key figures — 10-K (0001193125-26-071775) |url=https://www.sec.gov/Archives/edgar/data/1111485/000119312526071775/rxst-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-25}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.